Novartis AG – SIX:NOVN.SW

Add to watchlist

CHF 80.33

-8.48

-9.56%

Market closed

Open in about 1 hour

-11.23%

month

-11.23%

quarter

+5.49%

year

Market Cap	171.29B
Enterprise value	211.44B

P/E	11.26
EV/Sales	4.23
EV/EBITDA	10.72
Price/Sales	3.86
Price/Book	4.57
PEG ratio	0.32
EPS	7.40

Revenue	49.92B
EBITDA	18.54B
Income	15.24B
Revenue Q/Q	-8.23%
Revenue Y/Y	-4.40%

Profit margin	35.25%
Oper. margin	27.22%
Gross margin	74.92%
EBIT margin	27.22%
EBITDA margin	37.15%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Novartis AG (SIX:NOVN.SW): Profit margin
Jun 2023	13.93B	2.31B	16.62%
Sep 2023	12.09B	1.76B	14.56%
Dec 2023	11.77B	8.48B	72.01%
Mar 2024	12.12B	2.68B	22.18%

Novartis AG Financials Estimate

Q Y

Novartis AG (SIX:NOVN.SW): Analyst Estimates
Dec 2023	11.77B	8.48B	72.01%
Mar 2024	12.12B	2.68B	22.18%
Sep 2025	11.03B	4.21B	38.22%
Dec 2025	10.50B	4.11B	39.15%

Analysts Price target
Financials & Ratios estimates

Novartis AG (SIX:NOVN.SW): Earnings per share (EPS)
2023-02-01	1.39	1.52
2023-04-25	1.51	1.71

Novartis AG (SIX:NOVN.SW): Payout ratio
Payout ratio	43.31%

Novartis AG (SIX:NOVN.SW): Dividend Yield
2019	3.06%
2020	3.25%
2021	3.73%
2022	3.81%
2023	3.44%

Novartis AG (SIX:NOVN.SW): Debt to assets
Jun 2023	110979000000	59.04B	53.21%
Sep 2023	112697000000	74.45B	66.06%
Dec 2023	99945000000	53.19B	53.22%
Mar 2024	94334000000	54.57B	57.86%

Novartis AG (SIX:NOVN.SW): Cash Flow
Jun 2023	3.57B	-1.05B	-3.63B
Sep 2023	5.37B	-2.21B	-832M
Dec 2023	2.54B	-1.76B	-607M
Mar 2024	2.26B	-899M	-5.16B

Novartis AG alternative data

Novartis AG
Employees

Novartis AG (SIX:NOVN.SW): Employee count
Aug 2023	101,703
Sep 2023	103,000
Oct 2023	103,000
Nov 2023	101,703
Dec 2023	101,703
Jan 2024	101,703
Feb 2024	76,057
Mar 2024	76,057
Apr 2024	76,057
May 2024	76,057
Jun 2024	76,057
Jul 2024	76,057

Novartis AG
Executives

Insider	Age	Compensation
Dr. Vasant Narasimhan (1976) Chief Executive Officer	49	$4,670,000
Mr. Richard Saynor (1967) Chief Executive Officer of Sandoz	58	$3,490,000
Dr. James E. Bradner M.D. (1972) Pres of Novartis Institutes for Biomedical Research	53	$3,200,000
Ms. Susanne Schaffert Ph.D. (1967) Pres of Novartis Oncology	58	$2,760,000
Mr. Harry Kirsch (1965) Chief Financial Officer	60	$2,460,000
Dr. John Tsai (1967) Head of Global Drug Devel. & Chief Medical Officer	58	$2,110,000
Ms. Marie-France Tschudin (1971) Pres of Novartis Pharmaceuticals	54	$1,930,000
Mr. Steffen Lang Ph.D. (1967) Global Head of Technical Operations	58	$1,850,000
Mr. Robert Weltevreden (1969) Head of Customer & Technology Solutions	56	$1,440,000
Dr. Klaus Moosmayer Ph.D. (1968) Chief Ethics, Risk & Compliance Officer	57	$1,220,000

Frequently Asked Questions (FAQ)

What's the price of Novartis AG stock today?

One share of Novartis AG stock can currently be purchased for approximately $80.33.
When is Novartis AG's next earnings date?

Unfortunately, Novartis AG's (NOVN.SW) next earnings date is currently unknown.
Does Novartis AG pay dividends?

Yes, Novartis AG pays dividends and its trailing 12-month yield is 3.72% with 43% payout ratio. The last Novartis AG stock dividend of $0 was paid on 5 Sep 2025.
How much money does Novartis AG make?

Novartis AG has a market capitalization of 171.29B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 9.97% to 46.66B US dollars. Novartis AG earned 14.85B US dollars in net income (profit) last year or $1.71 on an earnings per share basis.
What is Novartis AG's stock symbol?

Novartis AG is traded on the SIX under the ticker symbol "NOVN.SW".
What is Novartis AG's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - General industry.
How do i buy shares of Novartis AG?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Novartis AG's key executives?
Novartis AG's management team includes the following people:
- Dr. Vasant Narasimhan Chief Executive Officer(age: 49, pay: $4,670,000)
- Mr. Richard Saynor Chief Executive Officer of Sandoz(age: 58, pay: $3,490,000)
- Dr. James E. Bradner M.D. Pres of Novartis Institutes for Biomedical Research(age: 53, pay: $3,200,000)
- Ms. Susanne Schaffert Ph.D. Pres of Novartis Oncology(age: 58, pay: $2,760,000)
- Mr. Harry Kirsch Chief Financial Officer(age: 60, pay: $2,460,000)
- Dr. John Tsai Head of Global Drug Devel. & Chief Medical Officer(age: 58, pay: $2,110,000)
- Ms. Marie-France Tschudin Pres of Novartis Pharmaceuticals(age: 54, pay: $1,930,000)
- Mr. Steffen Lang Ph.D. Global Head of Technical Operations(age: 58, pay: $1,850,000)
- Mr. Robert Weltevreden Head of Customer & Technology Solutions(age: 56, pay: $1,440,000)
- Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer(age: 57, pay: $1,220,000)
How many employees does Novartis AG have?

As Jul 2024, Novartis AG employs 76,057 workers.
When Novartis AG went public?

Novartis AG is publicly traded company for more then 30 years since IPO on 3 Aug 1995.
What is Novartis AG's official website?

The official website for Novartis AG is novartis.com.
How can i contact Novartis AG?

Novartis AG can be reached via phone at +41 61 324 11 11.

Novartis AG

novartis.com

Exchange:

SIX

Full time employees:

76,057

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

+41 61 324 11 11

Lichtstrasse 35
Basel, 4056

:
ISIN: CH0012005267
CUSIP: H5820Q150